{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:58:49Z","timestamp":1772161129377,"version":"3.50.1"},"reference-count":37,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Clinical Hypertension"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Data regarding the long\u2010term outcomes of generic antihypertensive drugs are limited. This nationwide retrospective database analysis aimed to evaluate the efficacy and safety of a generic versus brand\u2010name nifedipine for hypertension treatment. Patients who were prescribed generic or brand\u2010name nifedipine between January 1, 2008, and December 31, 2013, were identified from the National Health Insurance Research Database of Taiwan. The efficacy outcomes included all\u2010cause mortality and the composite cardiovascular (CV) outcome, including CV death, non\u2010fatal myocardial infarction, non\u2010fatal stroke, coronary revascularization, and hospitalization for heart failure. Safety outcomes included headache, peripheral edema, constipation, acute kidney injury, hypotension, syncope, new diagnosis of cancer, and cancer death. Among the 98\u00a0335 patients who were eligible for analysis, 21\u00a0087 (21.4%) were prescribed generic nifedipine. Both the generic and the brand\u2010name groups included 21\u00a0087 patients after propensity score matching. At a mean follow\u2010up of 4.1\u00a0years, the generic nifedipine was comparable to the brand\u2010name drug with regard to all\u2010cause mortality (7.2% vs. 7.1%; hazard ratio [HR] 1.02, 95% confidence interval [CI] 0.95\u20131.09) and the composite CV outcomes (11.6% vs. 11.9%; HR 0.97; 95% CI 0.92\u20131.03). The generic nifedipine was associated with higher rates of headache, peripheral edema, and constipation but a modest reduction in the risk of newly diagnosed cancer (7.1% vs. 7.8%; subdistribution HR 0.90, 95% CI 0.84\u20130.97). The risks of acute kidney injury, hypotension, syncope, and cancer death were not significantly different between the two groups. In conclusion, the generic nifedipine was comparable to the brand\u2010name drug with regard to the risks of all\u2010cause mortality and the composite CV outcome. The finding of cancer risk could be chance and should be interpreted with caution.<\/jats:p>","DOI":"10.1111\/jch.14070","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T18:49:30Z","timestamp":1602269370000},"page":"2296-2305","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety outcomes of one generic nifedipine versus ADALAT long\u2010acting nifedipine for hypertension management"],"prefix":"10.1111","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8557-1472","authenticated-orcid":false,"given":"Ying\u2010Chang","family":"Tung","sequence":"first","affiliation":[{"name":"Division of Cardiology Department of Internal Medicine Chang Gung Memorial Hospital Chang Gung University College of Medicine Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzyy\u2010Jer","family":"Hsu","sequence":"additional","affiliation":[{"name":"Division of Cardiology Department of Internal Medicine Chang Gung Memorial Hospital Chang Gung University College of Medicine Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia\u2010Pin","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Cardiology Department of Internal Medicine Chang Gung Memorial Hospital Chang Gung University College of Medicine Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu\u2010Chih","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Division of Cardiology Department of Internal Medicine Chang Gung Memorial Hospital Chang Gung University College of Medicine Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You\u2010Chia","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Computer Science National Chiao\u2010Tung University Hsien\u2010Chu Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen\u2010Jone","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine National Taiwan University Hospital Taipei Taiwan"},{"name":"Department of Emergency Medicine College of Medicine National Taiwan University Taipei Taiwan"},{"name":"Division of Cardiology Department of Internal Medicine National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0361-6348","authenticated-orcid":false,"given":"Pao\u2010Hsien","family":"Chu","sequence":"additional","affiliation":[{"name":"Division of Cardiology Department of Internal Medicine Chang Gung Memorial Hospital Chang Gung University College of Medicine Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,10,9]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62256-X"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61766-8"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60655-8"},{"issue":"10010","key":"e_1_2_11_5_1","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(15)00128-2","article-title":"Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"386","author":"Collaborators GRF","year":"2015","journal-title":"Lancet"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17741-1"},{"issue":"9943","key":"e_1_2_11_7_1","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0140-6736(14)61212-5","article-title":"Blood pressure\u2010lowering treatment based on cardiovascular risk: a meta\u2010analysis of individual patient data","volume":"384","author":"Collaboration BPLTT","year":"2014","journal-title":"Lancet"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b1665"},{"issue":"7","key":"e_1_2_11_9_1","first-page":"423","article-title":"The use of medicines in the United States: a detailed review","volume":"5","author":"Nash DB","year":"2012","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_11_10_1","volume-title":"FDA Bioequivalence Standards","author":"Lawrence XY","year":"2014"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02527-7"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000057420.27692.AD"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X132613"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2009.07.002"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70106-6"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70260-6"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4209"},{"key":"e_1_2_11_18_1","unstructured":"FDA Updates and Press Announcements on Angiotensin II Receptor Blocker Recalls. Available from:https:\/\/www.fda.gov\/drugs\/drug\u2010safety\u2010and\u2010availability\/fda\u2010updates\u2010and\u2010press\u2010announcements\u2010angiotensin\u2010ii\u2010receptor\u2010blocker\u2010arb\u2010recalls\u2010valsartan\u2010losartan"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2087"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112257"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.07.075"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2013.09.009"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.12.048"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/2012.jama.11975"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8008"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2010.03.001"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.758"},{"issue":"31","key":"e_1_2_11_28_1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10654-015-0104-8","article-title":"Generic versus brand\u2010name drugs used in cardiovascular diseases","volume":"2016","author":"Manzoli L","year":"2016","journal-title":"Eur J Epidemiol"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12326"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002763"},{"issue":"10","key":"e_1_2_11_31_1","doi-asserted-by":"crossref","first-page":"e003891","DOI":"10.1161\/CIRCOUTCOMES.117.003891","article-title":"Impact of the commercialization of three generic angiotensin II receptor blockers on adverse events in Quebec, Canada: a population\u2010based time series analysis","volume":"10","author":"Leclerc J","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)04277-8"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990315)85:6<1369::AID-CNCR21>3.0.CO;2-5"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113649"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00447-7"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-006-6312-4"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3181f98300"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S196293"}],"container-title":["The Journal of Clinical Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jch.14070","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jch.14070","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jch.14070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T18:22:08Z","timestamp":1693765328000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jch.14070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,9]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1111\/jch.14070"],"URL":"https:\/\/doi.org\/10.1111\/jch.14070","archive":["Portico"],"relation":{},"ISSN":["1524-6175","1751-7176"],"issn-type":[{"value":"1524-6175","type":"print"},{"value":"1751-7176","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,9]]},"assertion":[{"value":"2020-06-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}